X
PTCT icon

Xponance’s PTC Therapeutics PTCT Stock Holding History

Xponance’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$671K Buy
8,232
+869
+12% +$62.8K ﹤0.01% 962
2026
Q1 		$502K Buy
7,363
+1,191
+19% +$84.3K ﹤0.01% 1014
2025
Q4 		$469K Buy
6,172
+15
+0.2% +$1.09K ﹤0.01% 979
2025
Q3 		$378K Buy
6,157
+73
+1% +$3.8K ﹤0.01% 1066
2025
Q2 		$297K Sell
6,084
-288
-5% -$13.7K ﹤0.01% 1148
2025
Q1 		$325K Buy
6,372
+314
+5% +$15.7K ﹤0.01% 1072
2024
Q4 		$273K Buy
6,058
+570
+10% +$24.4K ﹤0.01% 1161
2024
Q3 		$204K Buy
+5,488
New +$184K ﹤0.01% 1252

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Xponance's PTCT Position: Q2 2026 in Review

Xponance increased its PTC Therapeutics (PTCT) stake by 12% in Q2 2026, buying an estimated $62.8K and bringing the position to 8,232 shares worth $671K. The position accounts for ﹤0.01% of the portfolio, ranked #962.

Xponance first reported a position in PTCT in Q3 2024 and has held it in 8 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Xponance held 8,232 shares of PTC Therapeutics worth $671K as of Q2 2026.
  • Xponance bought 869 PTC Therapeutics shares in Q2 2026, an estimated $62.8K.
  • PTC Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #962 holding.
  • Xponance first reported a position in PTC Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.